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Abstract
Corticosteroids are important in the treatment of inflammatory dermatoses, such as psoriasis. They have anti­
inflammatory, anti-proliferative and immunosuppressive effects. In this study, the effect of budesonide on prolifera­
tion, inflammatory cells and cytokines in psoriasis was investigated. In order to elucidate the time course of the dif­
ferent effects of corticosteroid treatment in psoriasis, six patients were treated for 3 weeks with budesonide 0.025% 
ointment (Preferid®), and biopsies were studied immuno his t oche mica lly, before treatment and after 1 and 3 weeks of 
treatment. Clinical scores together with staining with antibodies indicating proliferation, keratin 16, keratin 10, T- 
lymphocytes, monocytes, polymorphonuclear leukocytes, Langerhans cells, interleukin-1 a, (IL-la) interleukin-6 (IL- 
6), interleukin-8 (IL-8), tumor necrosis factor-a (TNF-a), and intercellular adhesion molecule-1 (ICAM-1) were per­
formed. ‘Psoriasis area’ and ‘severity index’ (PASI) scores were significantly reduced after 1 week and 3 weeks of treat­
ment. Epidermal hyperproliferation (Ki-67 binding) and suprabasal keratin 16 (Ks8.12) expression decreased within 
1 week, while keratin 10 (RKSE60) expression did not change. Five out of 6 patients showed cytokine levels (IL-la, 
IL-6, IL-8, and TNF-a; detected immunohistochemically) in the normal range, while 1 patient had highly increased 
cytokine levels. In this patient, cytokine levels decreased during treatment. In 4 patients, showing high dermal ICAM-1 
expression before treatment, a consistent reduction of ICAM-1 on endothelial cells was observed. The inflammatory 
infiltrate (T-]ymphocytes (Til), monocytes/macrophages (WT14), polymorphonuclear leukocytes (PMN, anti- 
elastase)) was reduced to some extent after 3 weeks. The number of Langerhans cells (OKT6) did not change. These 
results indicate that the psoriatic lesions, although clinically comparable, show interindividual differences in cytokine 
expression. Corticosteroid treatment for 1-3 weeks improves clinical scores and hyperproliferation. Cytokine levels 
are reduced during steroid treatment in the patient who showed high levels before treatment. To suppress the infiltrate 
entirely, longer steroid treatment is probably necessary. This may explain the relapse seen after short term cor­
ticosteroid therapy.
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1. Introduction
Lesional psoriatic skin is characterized by epi­
dermal hyperproliferation and disturbed keratin- 
ization in combination with epidermal leucocyte 
accumulation. Evidence is accumulating that re­
cruitment of cycling cells from the resting Go 
population is the mechanism of epidermal hyper­
proliferation in psoriasis [1,2]. The reduced ex­
pression of keratin 10 and the suprabasal 
expression of keratin 6 and 16 in psoriatic skin are 
indicators of the disturbed differentiation and
hyperproliferation [1,2,3].
Various cytokines play an important role in ho­
meostasis of normal skin and in skin pathology. 
Diverse stimuli trigger a cutaneous inflammatory 
response by directly inducing epidermal keratino- 
cytes to elaborate specific pro-inflammatory 
cytokines and adhesion molecules. After that, acti­
vation of dermal vascular endothelial cells and se­
lective accumulation of specific mononuclear cells 
in the dermis and epidermis can be seen [4]. In 
psoriasis, interleukin-1 a  (IL-la), interleukin-6 
(IL-6), interleukin-8 (IL-8), tumor necrosis factor­
ed (TNF-a), and interferon-7 (IFN-7) are con­
sidered to be of relevance to the pathogenesis and 
regression of a lesion [5-11]. Upon stimulation by 
cytokines [4], lesional endothelial cells and 
keratinocytes focally express intercellular adhe­
sion molecule-1 (ICAM-1), the intercellular adhe­
sion molecule which binds leucocyte function- 
associated antigen-1 (LFA-1) expressing granulo­
cytes and lymphocytes. Primarily T helper cells in­
filtrate the lesions, and subcorneal accumulation 
of granulocytes results in microabsesses [12,13],
Transforming growth factor-a (TGF-a) is a po­
tent autocrine growth factor for keratinocytes that 
can be induced by IFN-7 and TNF-a, and IL-6 
and IL-8 are also growth factors for keratinocytes 
[4], Epidermal acanthosis and keratiiu>cyte mitosis 
have been observed in delayed type hypersensitivi­
ty reactions and after intradermal injection of 
IFN-y [14]. Thus, abnormal hyperproliferation of 
keratinocytes has been suggested to be linked to 
cytokines released by the inflamed epidermis [4].
Keratin 16 expression have been reported to 
normalize after a minimum of 7-9 weeks of 
dithranol treatment [15]. Oxholm et al. [6]
reported that IL-6 intensity and extension were in­
creased in lesional as compared to non-lesional 
skin. Simultaneously with clinical improvement 
during PUVA therapy, the IL-6 staining became 
weaker. Recently, it was reported that ICAM-1 ex­
pression on papillary endothelium is reduced after
cyclosporin A (CsA) treatment, but not after 
PUVA or CD4 monoclonal antibody treatment 
[16]. In contrast, CsA treatment was not associ­
ated with any change in density and phenotype of 
dermal and epidermal leukocytes, in contrast with 
the marked diminution of the cellular infiltrate in­
duced by PUVA therapy, Horrocks et al. [17] 
reported that CsA treatment of psoriatic patients, 
reduced ICAM-1 expression on keratinocytes, but 
not on endothelial cells.
Corticosteroids have been of much benefit in the 
treatment of inflammatory dermatoses. They pos­
sess anti-proliferative, anti-inflammatory and im­
munosuppressive properties [18-20]. Corticoster­
oids directly suppress gene transcription (probably 
promoter regions of specific genes), and the mobi­
lization of mRNA. In addition non-nuclear modes 
of action have been postulated [21-23]. Recently 
it has been shown that various corticosteroids 
block the production of IL-la, IL-6, IL-8 and 
TNF-a by keratinocytes in vitro [5-7]. Cor­
ticosteroid treatment of psoriatic patients has been 
shown to restore the increased T4/T8 ratios [23] 
and to decrease the number and function of 
Langerhans cells [24,25]. However, it remains to 
be elucidated whether corticosteroids inhibit epi­
dermal growth and differentiation directly or alter­
natively whether corticosteroids reduce inflamm­
ation and inhibit epidermal growth indirectly. 
Budesonide 0.025% ointment (Preferid®, Brocades 
Pharma, Leiderdorp* The Netherlands) is a mod­
erate to potent corticosteroid [26,27], which is at 
least as effective as betamethasone-17-valerate
0.1% ointment [26], and has little effect on plasma 
cortisol levels and urinary cortisol excretion [27].
In order to elucidate the time course of different 
effects of corticosteroid treatment in psoriasis on 
proliferation and inflammation in vivo, six pa­
tients were treated for 3 weeks. The effect of treat­
ment with budesonide 0.025% ointment on 
parameters for proliferation, keratinization and 
inflammation was studied, using antibodies
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against an epitope on the nucleus of proliferating 
keratinocytes (Ki-67), against keratin 13/16 
(Ks8.12) and keratin 10 (RKSE60), In the same 
biopsies the presence of IL-la, IL-6, IL-8, or 
TNF-a and ICAM-1 expression was assessed 
using specific antibodies. The inflammatory cells 
were analyzed using monoclonal antibodies 
against T-lymphocytes (Til), monocytes/macro­
phages (WT14), polymorphonuclear leukocytes 
(PMN; anti-elastase) and Langerhans cells 
(OKT6). The response of the psoriatic lesions to 
budesonide was assessed after 1 week and 3 weeks 
treatment in order to determine how the various 
aspects of the lesions are modulated by this treat­
ment in vivo.
2. Materials and methods
2A. Patients
Six patients (one male and five females) with 
moderate chronic plaque psoriasis participated in 
the study. Their age varied from 24-67 with an 
average of 47.5 years. They had used no systemic 
treatment for at least 2 months, and no topical 
treatment for at least 2 weeks. Patients applied 
budesonide ointment 0.025% (Preferid®, Brocades
Pharma B.V., Leiderdorp, The Netherlands) twice 
daily thinly and evenly to the psoriatic lesions for 
3 weeks. Clinical scores were recorded before 
treatment, after 1 week and after 3 weeks of treat­
ment for the lesions on the upper extremities, 
trunk and lower extremities. Erythema (E), infil­
tration (I) and scaling (S) of the lesions were 
assessed using a 5-point scale: 0, no cutaneous in­
volvement; 1, slight; 2, moderate; 3, severe; 4, 
severest possible involvement. The area (A) of the 
body surface that was involved was recorded using 
a 7-point scale: 0, no involvement, 1, < 10%; 2, 
10-29%; 3, 30-49%; 4, 50-69%; 5, 70-89%; 6, 
90-100% of the body surface involved. The PÀSI- 
score was calculated as follows:
upper extremities: 0.2 X A(E+I+S) +
trunk: 0.3 x A(E+I+S) +
lower extremities: 0.4 X A(E+I+S)
Punch biopsies (<f> 4 mm) were taken from a 
nummular to palmsized lesion before treatment,
after 1 week and after 3 weeks of treatment. For 
staining with anti-IL-a, IL-6, ICAM-1, IL-8, and 
TNF-o: normal skin biopsies from healthy 
volunteers were used as a control.
This study was approved by the medical ethical 
committee, and all patients were informed of the 
nature of the experiment and gave written consent.
2.2. Immunohistochemical stainings
2 2 A. Antibodies. The primary antibodies used 
are listed in Table 1.
2.2.2. Tissue processing. The biopsies were im­
mediately embedded in Tissue-Tek OCT Com­
pound (Miles Scientific, Elkhart, USA), snap 
frozen in liquid nitrogen and stored at -80°C until 
further processing. Normal healthy skin and un­
treated psoriatic lesional skin from other patients 
were processed in parallel with the experimental 
tissues. Seven-^m cryostat sections were placed on
0.1% poly-L-lysine coated slides. After air-drying 
the sections were fixed for 10 min at room temper­
ature in acetone, acetone/ether 60/40% or in an 
aqueous 4% paraformaldehyde solution (see Table 
1). The sections destined for cytokine staining and 
for ICAM-1 staining were processed immediately. 
The others were stored at -80°C until further pro­
cessing.
Four immunohistochemical techniques were 
used to visualize the different markers (see Table 
1). For the direct and indirect peroxidase tech­
nique, the slides were incubated with the primary 
antibodies in the proper dilutions (see Table 1) for 
30 min. After repeated washing, the slides for indi­
rect staining were incubated for 30 min with a 1:50 
dilution in phosphate buffered saline (PBS) of per­
oxidase conjugated rabbit-anti-mouse-immuno- 
globulin (Dakopatts, Copenhagen, Denmark). 
After washing and pre-incubation in sodium ace­
tate buffer, pH 4.9 (NaOAc-buffer), the slides were 
stained with 3-amino-9-ethylcarbazole (AEC, 
Sigma, St. Louis, USA)/H202 in NaOAc-buffer 
for 10 min.
For the peroxidase-anti-peroxidase technique 
the slides were incubated for 60 min with the 
monoclonal antibodies. After washing, the slides 
were incubated with rabbit-anti-mouse immuno­
globulin (RAM-Ig, Dakopatts, Copenhagen, Den­
mark) 1:25 in PBS for 20 min. After washing they
Table 1
List of primary antibodies, specificities, fixation and immunohistochemical procedures
188 E .M .G J . de Jong et ah /  Journal o f  Dermatological Science 9 (1995) 185-194
Antibody
clone
Specificity Mono/poly Fixation Dilution first 
AB
Imunohisto-
chemical
procedure
Source
Ki-67 Human Ki-67- 
antigen
M A/E2 1:40 *P-SAb5 Dakopatts, Copenhagen, 
Denmark
RKSE60 Keratin 10 M A 3 1:10 *P-SAb F. Ramaekers, Maastricht, 
The Netherlands
Ks8.12 Keratin 13,16 M A 1:25 *P-SAb Sigma, St Louis, USA
84H10 ICAM-1 M A 1:50 AB6 Immunotech, Marseille, 
France
Anti-IL-Ice IL-Ict P l A 1:50 AB Genzyme, Cambridge, 
USA
Anti-IL-6 IL-6 P* PF4 1:1000 AB Gift from L. May, New 
Haven, Connecticut,
USA
Anti-IL-8 IL-8 P 1 PF 1:50 AB AMS, Oxford, UK
Anti-TNF-c* TNF-a P 1 PF 1:1000 AB Genzyme, Cambridge, 
USA
TU CD2 M A 1:100 PAP7 Dakopatts, Copenhagen, 
Denmark
WT14 CD14 M A 1:100# PAP W. Tax, Nijmegen, The 
Netherlands
Anti-elastase Leukocyte-
elastase
P A 1:100 D 8 Serotec, Oxford, UK
OK.T6 CDla M A 1:100 PAP Ortho Diagnostic Systems, 
Raritan, USA
Notes:
!A11 polyclonal antibodies were raised in rabbit. 2A/E, acetone/ether 60/40%. 3A, acetone, 4PF, 4% aqueous paraformaldehyde, 
5*P-SAb, peroxidase linked second antibody. 6AB, streptavidin-biotin method. 7PAP, peroxidase-anti-peroxidase method. 8D, direct 
method.
were incubated with peroxidase-anti-peroxidase- 
complexes (PAP-complexes, Dakopatts, Copen­
hagen, Denmark) 1:100 in PBS for 20 min. Incuba­
tions with RAM-Ig, and with the PAP-complexes 
were repeated. The slides were stained in the same 
solution of AEC/H20 2 in NaOAc-buffer, as men­
tioned above.
For the avidin-biotin method the sections were 
pre-incubated with a 10% normal goat serum 
(Dakopatts, Copenhagen, Denmark) solution, and 
incubated with the primary antibodies for 1 h. 
After washing, they were incubated for 30 min 
with biotinylated goat-anti-rabbit immunoglobu­
lin (Dakopatts, Copenhagen, Denmark), diluted 
1:500, or with biotinylated F(ab)2 fragment of 
rabbit-anti-mouse immunoglobulin (Dakopatts,
Copenhagen, Denmark), diluted 1:200 (after 
84H10 for ICAM-1). After washing, the sections 
were incubated for 30 min with a 1:200 dilution of 
peroxidase labelled streptavidin-biotin complex 
(Dakopatts, Copenhagen, Denmark). The colour 
reaction was performed by incubation with the 
AEC/H20 2 solution. All slides were counterstain­
ed with Mayers haematoxylin (Sigma, St. Louis, 
USA) and mounted in glycerol gelatin (Sigma, St. 
Louis, USA).
2.3. Scores
Histological changes in the epidermal and der­
mal compartment were assessed by two separate 
investigators in a double blind approach, using a 
semi-quantitative scale [28]: Epidermis: 0, no
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staining; 1, sporadic staining; 2, minimal staining; 
3, moderate staining; 4, moderate-pronounced 
staining; 5, pronounced staining. Dermis: 0, no 
stained cells; 1, sporadic; 2, 1 -25% of the infiltrate 
cells stained; 3, 26-50%; 4, 51-75%; 5, 76-99%; 6, 
100% of the infiltrate cells stained. Ki-67-positive 
nuclei were counted/nun length of epidermis.
2.4. Statistical analysis 
The Wilcoxon ranking test for matched pairs 
was used for the statistical analysis.
3. Results
3.1. Clinical response
The treatment with budesonide was well- 
tolerated. After 1 week of treatment, the PASI- 
score had diminished in a statistically significant 
manner (P < 0.03) from 5.36 =fc 0.98 
(Mean ± S.E.M.) to 3.63 ±  0.61. After 3 weeks 
of treatment, the average PASI-score was 
2.12 ± 0.58 (P < 0.03 as compared to the situ­
ation before treatment).
3.2. Immunohistochemical observations 
Assessment of epidermal proliferation and kera-
tinization, before and after 1 and 3 weeks of treat­
ment is summarized in Table 2 and illustrated in 
Fig. 1. The number of Ki-67 stained nuclei 
diminished significantly (P < 0.03) after 1 week of 
treatment. After 3 weeks, their numbers had 
diminished further (P < 0.03). Suprabasal staining 
with Ks8.12 (keratin 16) diminished significantly 
after 1 week (P < 0.03) and continued to decline
Table 2
Epidermal proliferation and keratinization during treatment 
with budesonide (mean =t S.E.M.)
Ki-67 binding 
(positive nuclei)
Suprabasal Ks8.12 
staining mm length 
of epidermis
Before treatment 153 ±  24 4.5 ±  0.6
After 1 week 44 ±  10* 2.5 ±  0.8*
After 3 weeks 30 ±  11* 2.8 ±  1.8
♦Indicates a statistically significant reduction compared to 
score at previous visit.
between 1 and 3 weeks of treatment. In contrast, 
keratin 10 showed no significant changes during 
treatment with budesonide.
Although the lesions biopsied, clinically had a 
comparable appearance, a large interindividual 
variation was seen with respect to the expression 
of the cytokines in untreated psoriatic skin. In 5 of 
the 6 patients the untreated lesions showed low IL- 
\<x expression in the epidermis; this level did not 
change during treatment. In one patient, IL -la  ex­
pression was very high, and declined during 1 and 
further after 3 weeks treatment (see Table 3). In 
addition, in 5 out of 6 patients the untreated le­
sions showed low levels in the epidermis of IL-6, 
IL-8 and TNF-a, which did not change during 
treatment (see Table 3). In the same patient, show­
ing a marked IL-la staining, IL-6, IL-8 and TNF- 
a staining were also pronounced in the epidermis. 
Within 1 week of treatment with budesonide these 
cytokines were reduced markedly in this patient, 
and they had normalized in 3 weeks. Fig. 1 il­
lustrates the expression of TNF-a.
Epidermal staining of ICAM-I in untreated 
psoriatic plaques was high in only one patient. In 
this patient epidermal ICAM-1 expression was 
reduced after 1 week treatment, and absent after 3 
weeks. T 11 stained cells (T-cells) and Langerhans 
cells in the epidermis did not change during treat­
ment (Table 4). However, epidermal WT14-stained 
cells (monocytes/macrophages) diminished signifi­
cantly (P < 0.03) in 3 weeks, and the PMN in­
filtrate decreased steadily although not signifi­
cantly.
ICAM-1 staining of the capillaries was high in 4 
patients, and diminished markedly within the first 
week of treatment (P  < 0,03). The dermal in­
filtrate declined between 0 and 3 weeks (P <  0.05). 
The number of PMNs in the dermis diminished 
significantly within 1 week (P  < 0.05), In contrast 
the percentage of T-lymphocytes, monocytes/mac­
rophages and Langerhans cells remained unchang­
ed during the observation period.
4. Discussion
In the biopsies of psoriatic patients before 
budesonide treatment, we found high Ki-67 expres­
sion, high suprabasal keratin 16, and decreased
190 E.M.G.J. de Jong et al. /  Journal o f  Dermatological Science 9 (1995) 185-194
A C
¡ 0
•w;2v '":3 •
' f e - .
£:*"
i-V /.
■/Vi v
ÌV';V.
*•%V ■■.. • '
■• :.;M
• »  1
. ' ' v : ^  ' . r  A
'.<K?v .
■M ' ,  , J Z m . , ,
j l " .
>i  * ’ V  < / V
: -m : '^V *>.s>V l  ».  • • «Vi -v* * ìf''Sl'■\ ■&!$ V ’* ■' i ".ivf ’ il ¥.1
.7* . ‘¿A  l 
5F i: .:P ■ M'r ^
WkM ' w ß -*, J ’A
%
it rvmtf/
.< . / jv w -»-C; ■*' v ,
f ^ tisu tA Ä4|*| .  v
%1 .?
*■ e Ä
r.i'W*v ■ •
Ét é;;Yf _
Mw J*Tf z, t
5, Si
i r ' . '  y0èif, ■ */&&. t  . i  «H?
:.■■►'•• w '
- ' 'w - ì -
f t r S
H i
■W-jJ
4Z r.
il»-' ' •
M.
^  :
"  V ««effe•» &y **
, y  r f r  ,
* à * s r  ^
^ • T ' \ :  < "  M I  ,#A
<W
>
s ÌL '#'.W.Ù lk "» »%H ìpW. I ' •
■ ■ ? t > ■:
* ►
r#5
I‘' i  ^   ^ v! , ;  ,  '  ■ •-*. *
■■■ • »  ^  ' #  ■%
‘ Ati
ì  - • ,
'  V'*C ■■■■ '■ ' : 1.h»S
s ' Ài .• .  •' *%
• i I «  *•* •,J - 'Ä :w  ".: .
••■!.\ ', V *  ,  J f  
* * 4 -►.$’•’•? " •& *  » #
,, f>* U* •*
A V ^ ' i f *
' • Lé3' *'' •# .r»:.. *::•>• ¿5' • . * W , •* • • ' ...* * . -8 r ^ W ' • r - *: ÌJ-* ■ ■» - ■%,■ .. v .  . # . s. -
ifr*. ,S fl- * ^
" •  '  '  » ¿ r  j & c W ì t L  .►ii  • &  : • '  • :•; .  .-ii-H ■
" i t e ■
f .*. a 
m  i > i
\
'*$* : «1 ■**& $3 ir
"I \
. t
. .  k a . . 0'^ 4 * té è* M t  ' - M  - ; .  « i s . .
D
1 .
'•  ->:Ì
Fig. 1. Inununohistochemical localization ofTNF-a in a psoriatic lesion: (À), before; (B), after 1 week; (C), after 3 weeks treatment 
with budesonide; (D), in normal human skin ( X 400).
keratin 10 expression. This indicates a clear hyper- 
proliferative status* as in normal skin, Ks8.12- 
binding is virtually absent, and the numbers of Ki- 
67 positive nuclei are low (30-50/mm length of
epidermis) [1,2]. In this study we found only one 
patient with intense staining for IL-la, IL-6, IL-8 
and TNF-a. The other patients showed cytokine 
levels in the range of normal skin. ICAM-1 expres­
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Table 3
Cytokine expression in normal human epidermis, 1 patient (‘high’) with high cytokine levels, and 5 other patients (‘low’) with tow 
cytokine levels
IL-la IL-6 IL-8 TNF-a
Normal human skin 3 1 0 2
'High ’ psoriasis patient
Before 3 3 2 4
After 1 week 1 2 0 2
After 3 weeks 0 0 0 1
‘Low* psoriasis patients
Before 1.6 ±  0.4 0.6 óz 0.2 0.5 ± 0.3 1,6 ±  0.2
After 1 week 1.6 ±  0.4 0.6 =fc 0.2 0,4 dh 0.2 1*6 i  0.2
After 3 weeks 2 0.7 ±  0.3 0 1.7 db 0.3
sion in keratinocytes was also only high in this one 
particular patient. ICAM-1 expression on endo­
thelial cells was increased in most patients. We
found quite high numbers of PMN and mono­
cytes/macrophages and a substantial amount of T-
lymphocytes.
In literature, it is described that IL-la is present 
in both normal and psoriatic skin [29,30], and that 
IL-6, IL-8, or TNF-a is low or absent in normal 
skin, and is increased in untreated psoriatic lesions 
[31-35]. ICAM-1-staining in untreated psoriatic 
lesions is focal in most cases and absent in normal 
skin [36]. More recently, contradictory reports 
have been published on immunoreactive cytokine 
levels in psoriatic lesions [37]. It has been sug­
gested, that technical problems, or different anti­
bodies, cause these variations. However, as can be
seen from our study, clinically comparable, un­
treated psoriatic lesions, from different psoriatic 
patients show different cytokine patterns, 
although processed and stained in exactly the same 
way. This means, that the differences are real, and
that either each patient has his own psoriasis, or 
that the stage of development of the lesion is of 
crucial importance [32,35,38].
During 3 weeks of treatment with budesonide, a
pronounced reduction was observed with respect 
to epidermal hyperproliferation. Various studies 
have demonstrated an effect of corticosteroids on 
mitotic activity of keratinocytes in culture and in
situ in the epidermis [8,9]. In a previous investiga­
tion on the interference of corticosteroids with the 
response to sellotape stripping, it was shown that 
the recruitment of cycling cells from the resting
Table 4
Markers for inflammation during treatment with budesonide (mean ±  S.E.M.)
Anti-elastase T i l  positive cells WT14 positive cells OK.T6 positive cells ICAM-1 positive celli
Epiderm Derm Epiderm Derm Epiderm Derm Epiderm Derm Epiderm Derm
Before 
After 1 week
After 3 weeks
1.6 ± 1.2 
0.6 d= 1.0 
0.2 ± 0.4
1.6 ±  0.5 
0.8 db 0.4* 
0.8 ± 0.4
2.3 ± 0.8 
1.8 ± 0.4
1.4 ± 0.6
3.6 ds 0.8 
3,3 dt 1,0 
3.8 ± 0.8
1.6 db 0,5
1.3 ± 0.5
1.4 =b 0.8*
2,3 ± 0.8 
2.5 ± 0.5
2.2 ± 0.4
2.8 db 0.4 
3.1 ±0.4
2.8 db 0.8
1.8 ± 0.4 
2.5 ± 0.5 
1.4 ± 0.5
0.3 ±  0.3 
0.2 ± 0.2 
0
2.0 :fc 0.2 
1.2 ±  0.1* 
1,1 ± 0.1
♦Indicates a statistically significant reduction compared to scores at previous visit.
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Gq population was arrested [39], During treat­
ment with budesonide, significant inhibition was 
observed of keratin 16 expression in the supra-
basal compartment (Ks8.12 binding), also in­
dicating reduced hyperproliferation [3].
The staining with antibodies against the cyto­
kines revealed highly variable results. Although a 
consistent reduction of all the cytokines was 
observed after treatment with budesonide in the 
patient demonstrating a marked staining in the un­
treated lesional skin, in all the remaining patients 
only a mild to moderate staining was observed 
before treatment, without a significant reduction 
during budesonide treatment. Further studies on 
cytokine patterns in the psoriatic lesion in a larger 
group of patients are needed to elucidate this fur­
ther. Sticherling et al, [10] showed low im- 
munoreactivity of IL -8 in lesional psoriatic skin. 
This is in line with the low levels of IL-8 in the 
pretreatment biopsies of our patients. In vitro 
studies demonstrated inhibition of the stimulated 
transcription of IL - la , IL-6, IL-8, or TNF-a by 
corticosteroids, including budesonide [5]. The pre­
sent study shows, that if cytokine levels are high in 
vivo before treatment, a reduction of cytokine 
staining can be seen after treatment with bude­
sonide.
This study suggests that there are at least two 
populations in psoriatic patients in terais of 
cytokine expression. Corticosteroids have been 
shown to interfere with inflammation control in 
various ways. They modulate the accumulation 
and functioning of PM N  [40], T-lymphocytes [24], 
and Langerhans cells [24,25]. The first significant 
reduction of PM N  accumulation was observed 
within the first week of treatment and coincided 
with a substantial reduction of epidermal prolifer­
ation, Interestingly, a significant reduction of 
ICAM-1 expression in the capillaries occurred, 
whereas no statistically significant reduction of the 
percentage o f T-cells was noticed.
From the present study it can be concluded that 
epidermal hyperproliferation is reduced during 
budesonide treatment. This seems not to be the 
result of a reduction o f the inflammatory infiltrate. 
The change in cytokines and infiltrate composition 
was less pronounced probably due to relatively 
low pretreatment values. Epidermal proliferation,
therefore, seems an important target in the anti­
psoriatic working principle of budesonide. To 
elucidate whether changes in cytokines precede 
changes in proliferation and inflammation, the 
early changes induced by corticosteroid treatment 
should be investigated. The period between 0 and 
7 days seems to be of crucial importance in 
unravelling this cascade. Following cessation of 
treatment with corticosteroids a relatively fast re­
lapse occurs [40-43]. It could be of value to deter­
mine whether prolonged treatment with corti­
costeroids, until the point of resolution of inflam­
mation was reached, might lengthen the remission 
periods.
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